Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, Wang Q, Than H, Patel AB, Heaton WL, Eiring AM, Clair PM, Gantz KC, Redwine HM, Swierczek SI, Halverson BJ, Baloglu E, Shacham S, Khorashad JS, Kelley TW, Salama ME, Miles RR, Boucher KM, Prchal JT, O'Hare T, Deininger MW. Yan D, et al. Among authors: baloglu e. Clin Cancer Res. 2019 Apr 1;25(7):2323-2335. doi: 10.1158/1078-0432.CCR-18-0959. Epub 2018 Dec 18. Clin Cancer Res. 2019. PMID: 30563936 Free PMC article.
Clinical translation of nuclear export inhibitors in cancer.
Senapedis WT, Baloglu E, Landesman Y. Senapedis WT, et al. Among authors: baloglu e. Semin Cancer Biol. 2014 Aug;27:74-86. doi: 10.1016/j.semcancer.2014.04.005. Epub 2014 Apr 19. Semin Cancer Biol. 2014. PMID: 24755012 Review.
Nucleo-cytoplasmic transport as a therapeutic target of cancer.
Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C. Gravina GL, et al. Among authors: baloglu e. J Hematol Oncol. 2014 Dec 5;7:85. doi: 10.1186/s13045-014-0085-1. J Hematol Oncol. 2014. PMID: 25476752 Free PMC article. Review.
CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling.
Sun H, Lin DC, Cao Q, Guo X, Marijon H, Zhao Z, Gery S, Xu L, Yang H, Pang B, Lee VK, Lim HJ, Doan N, Said JW, Chu P, Mayakonda A, Thomas T, Forscher C, Baloglu E, Shacham S, Rajalingam R, Koeffler HP. Sun H, et al. Among authors: baloglu e. Cancer Res. 2016 May 1;76(9):2687-97. doi: 10.1158/0008-5472.CAN-15-1572. Epub 2016 Mar 8. Cancer Res. 2016. PMID: 26956669 Free article.
KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
Etchin J, Berezovskaya A, Conway AS, Galinsky IA, Stone RM, Baloglu E, Senapedis W, Landesman Y, Kauffman M, Shacham S, Wang JC, Look AT. Etchin J, et al. Among authors: baloglu e. Leukemia. 2017 Jan;31(1):143-150. doi: 10.1038/leu.2016.145. Epub 2016 May 23. Leukemia. 2017. PMID: 27211268 Free PMC article.
99 results